Morgan Stanley’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-55,191
| Closed | -$2.9M | – | 7293 |
|
|
2020
Q3 | $2.9M | Sell |
55,191
-264,636
| -83% | -$11M | ﹤0.01% | 3295 |
|
|
2020
Q2 | $10.6M | Buy |
319,827
+37,390
| +13% | +$1.19M | ﹤0.01% | 1910 |
|
|
2020
Q1 | $7.68M | Sell |
282,437
-239,674
| -46% | -$6.67M | ﹤0.01% | 2016 |
|
|
2019
Q4 | $10.3M | Sell |
522,111
-73,101
| -12% | -$1.17M | ﹤0.01% | 2411 |
|
|
2019
Q3 | $7.71M | Buy |
595,212
+134,675
| +29% | +$1.63M | ﹤0.01% | 2391 |
|
|
2019
Q2 | $5.73M | Buy |
460,537
+403,661
| +710% | +$5.36M | ﹤0.01% | 2785 |
|
|
2019
Q1 | $826K | Sell |
56,876
-120,089
| -68% | -$1.53M | ﹤0.01% | 4243 |
|
|
2018
Q4 | $1.95M | Sell |
176,965
-70,075
| -28% | -$975K | ﹤0.01% | 3790 |
|
|
2018
Q3 | $6.5M | Buy |
247,040
+37,970
| +18% | +$1.03M | ﹤0.01% | 2902 |
|
|
2018
Q2 | $4.28M | Buy |
209,070
+42,600
| +26% | +$914K | ﹤0.01% | 3327 |
|
|
2018
Q1 | $3.02M | Sell |
166,470
-25,719
| -13% | -$429K | ﹤0.01% | 3594 |
|
|
2017
Q4 | $2.68M | Buy |
192,189
+27,069
| +16% | +$366K | ﹤0.01% | 3759 |
|
|
2017
Q3 | $3.06M | Buy |
165,120
+20,553
| +14% | +$344K | ﹤0.01% | 3471 |
|
|
2017
Q2 | $2.44M | Sell |
144,567
-129,157
| -47% | -$1.97M | ﹤0.01% | 3620 |
|
|
2017
Q1 | $3.65M | Buy |
273,724
+28,069
| +11% | +$440K | ﹤0.01% | 3208 |
|
|
2016
Q4 | $3.7M | Buy |
245,655
+177,260
| +259% | +$2.34M | ﹤0.01% | 3316 |
|
|
2016
Q3 | $800K | Buy |
68,395
+5,829
| +9% | +$68.5K | ﹤0.01% | 4203 |
|
|
2016
Q2 | $676K | Buy |
62,566
+6,524
| +12% | +$67.3K | ﹤0.01% | 4255 |
|
|
2016
Q1 | $518K | Sell |
56,042
-13,717
| -20% | -$148K | ﹤0.01% | 4419 |
|
|
2015
Q4 | $1.03M | Buy |
69,759
+38,470
| +123% | +$644K | ﹤0.01% | 4023 |
|
|
2015
Q3 | $514K | Buy |
31,289
+4,928
| +19% | +$101K | ﹤0.01% | 4594 |
|
|
2015
Q2 | $601K | Sell |
26,361
-204
| -0.8% | -$4.06K | ﹤0.01% | 4584 |
|
|
2015
Q1 | $403K | Sell |
26,565
-371,142
| -93% | -$4.82M | ﹤0.01% | 4793 |
|
|
2014
Q4 | $4.79M | Sell |
397,707
-56,123
| -12% | -$641K | ﹤0.01% | 2764 |
|
|
2014
Q3 | $5.15M | Buy |
453,830
+414,922
| +1,066% | +$4.73M | ﹤0.01% | 2615 |
|
|
2014
Q2 | $471K | Sell |
38,908
-159,648
| -80% | -$1.89M | ﹤0.01% | 4620 |
|
|
2014
Q1 | $2.31M | Buy |
198,556
+29,833
| +18% | +$505K | ﹤0.01% | 3294 |
|
|
2013
Q4 | $2.98M | Buy |
168,723
+24,043
| +17% | +$404K | ﹤0.01% | 3063 |
|
|
2013
Q3 | $2.08M | Buy |
144,680
+115,713
| +399% | +$1.77M | ﹤0.01% | 3178 |
|
|
2013
Q2 | $437K | Buy |
+28,967
| New | +$382K | ﹤0.01% | 4351 |
|
Morgan Stanley's MNTA Position: Q4 2020 in Review
Morgan Stanley sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 55,191 shares — an estimated $2.9M sold.
Morgan Stanley first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $10.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Morgan Stanley reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Morgan Stanley sold 55,191 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $2.9M.
- Morgan Stanley first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- Morgan Stanley's Momenta Pharmaceuticals, Inc. position peaked at $10.6M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Morgan Stanley's 13F filing for Q4 2020, filed 16 Feb 2021.